Analytical Data
-
Gene name
C1QTNF5
- Application
-
Alternative Names
CTRP5; LORD
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BXJ0
-
Expression Region
Ser16~Ala243
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FANCD2 is a crucial protein involved in the Fanconi anemia (FA) pathway, a critical DNA repair mechanism that maintains genomic stability. This pathway is essential for the repair of interstrand DNA cross-links, which can be induced by various agents, including certain chemotherapeutic drugs and environmental toxins. Mutations in the FANCD2 gene are associated with Fanconi anemia, a rare genetic disorder characterized by increased susceptibility to cancer, bone marrow failure, and specific congenital abnormalities. The study of recombinant FANCD2 protein is significant for understanding its role in DNA repair and the FA pathway. By producing and purifying recombinant FANCD2, researchers can investigate its functional properties, regulatory mechanisms, and interactions with other proteins involved in the DNA damage response. Furthermore, this research holds potential for developing targeted therapies for FA-related malignancies and improving the efficacy of chemotherapeutic regimens that rely on the proper functioning of the FA pathway. Advances in the characterization of FANCD2 not only enhance our understanding of DNA repair mechanisms but also contribute to the development of clinical strategies to combat cancers associated with Fanconi anemia. As such, recombinant FANCD2 research is pivotal in bridging basic science with therapeutic applications, offering insights that could lead to novel treatments for patients suffering from FA and other related conditions.
